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We had previously reported that glycosphingolipids (GSL) support human immunodeficiency virus type 1 (HIV-1) entry. In this study, we
further examined this issue by expressing HIV-1 receptors in GSL-deficient GM95 cells. GM95 cells expressing low levels of CD4 and
CXCR4 or CCR5 did not support HIV-1 Env-mediated fusion. However, higher expression of these receptors rendered GM95 cells highly
susceptible to fusion with cells expressing appropriate HIV-1 envelope glycoproteins (HIV-1 Envs). The GM95 cells exhibited a different
fusion phenotype when compared with GSL+ NIH3T3 cells bearing similar receptor levels. Fusion of GM95 targets expressing higher levels of
CD4 and coreceptors occurred at 25jC and was sensitive to cholesterol depletion or disruption of the cytoskeleton. In contrast, the fusion
threshold of NIH3T3CD4X4/R5 targets was at z 28jC as previously reported and was insensitive to cholesterol depletion or cytoskeletal
network disruption. On the basis of these observations, we propose that target membrane GSLs support HIV-1 Env-mediated fusion at low
density of receptors by stabilizing receptor pools in natural targets.
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susceptible cells by fusion of the viral membrane with the cell
plasma membrane. This process is mediated by the interac-
tion of the HIV-1 envelope glycoprotein (HIV-1 Env) with
CD4 on the host cell surface and requires additional core-
ceptors such as CXCR4 and CCR5 that determine the tropism
of different HIV-1 isolates (Chan and Kim, 1998; Dimitrov,
1997; Moore et al., 1993). Several viral envelope glycopro-
tein oligomers then assemble into a viral fusion machine,
forming a molecular scaffold that brings the viral and target
cell membranes into close apposition and allows for the
subsequent fusion events (Freed et al., 1992; Jones et al.,
1998). Previous reports suggest that glycosphingolipids
(GSL) may be involved in the assembly and functioning of
the HIV-1 fusion machine. This is because inhibition of target
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2000), and that fusion activity can be recovered following
addition of purified GSLs [such as globotriaosylceramide
(Gb3) and monosialoganglioside (GM3)] to the impaired
cells (Hug et al., 2000; Puri et al., 1998). Moreover, studies
using monolayers of purified GSLs provide evidence for
CD4-induced interactions between HIV-1 gp120 and GSLs,
Gb3, and GM3 (Fantini et al., 2000; Hammache et al., 1999).
These observations have led to the hypothesis that plasma
membrane GSL-enriched microdomains are preferential sites
for assembly of the HIV-1 fusion machine (Hammache et al.,
1999). GSLs have also been proposed as attachment factors
for initial capture of HIV-1 by intestinal epithelial cells.
Bomsel (1997) reported that the infectious HIV could cross
a tight human epithelial cell barrier by transcytosis.
To further analyze the contribution of GSLs in CD4-
mediated HIV-1 entry and HIV-1 Env-mediated membrane
fusion, we have examined the susceptibility of a GSL-
deficient mouse melanoma skin fibroblast cell line, GM95,
to HIV-1 fusion. GM95 cells have a primary defect in the
ceramide glucosyl transferase (EC 2.4.1.80), which is re-
quired for the synthesis of glucosyl ceramide, the precursor
for over 300 different GSL species in animal cells (Ichikawa
et al., 1994). The overall lipid composition of the mutant
GM95 and the parent MEB4 cells have been reported to be
similar except upregulation of sphingomyelin (SM) in GM95
cells to compensate the GSL deficiency in these cells (Oster-
meyer et al., 1999). However, absence of GSLs in the GM95
cells had no effect on the formation of plasma membrane
microdomains (rafts) (Ostermeyer et al., 1999).
We report here that the defect in GSL biosynthesis in
GM95 cells had no effect on the biosynthesis and expression
of the HIV receptors, CD4, CXCR4, and CCR5. Our studies
show that the HIV-1 Env-mediated fusion can take place in
the absence of GSLs provided receptor/coreceptors are
expressed at relatively high levels in the target membrane.
However, at low expression of receptors, GSLs are required
for HIV-1 fusion. These findings suggest that GSLs play a
role in the recruitment of receptor(s) and receptor clustering
to promote HIV-1 entry. In addition, an unexpected lower
temperature requirement, dependence on the membrane cho-
lesterol, and intact cytoskeletal network for fusion of GSL-
deficient GM95 targets suggest that GSLs contribute to the
overall fusion process in natural targets. We discuss our
results in the framework of GSL-mediated stabilization of
the receptor/coreceptor pools.Results
GM95 cells expressing elevated levels of CD4 and
chemokine receptors fuse with HIV-1 Env-expressing cells
In our first series of experiments, we tested fusion
activity of GM95 cells transiently expressing CD4 and
CXCR4. GM95 cells were infected with the vacciniarecombinants encoding the genes for wild-type CD4
(vCB3) and wild-type human CXCR4 (vacc-CXCR4) for
10–16 h at 37jC. To monitor fusion, we labeled GM95
cells with the aqueous fluorescent probe calcein and HIV-1
Env-expressing cells with CMTMR before fusion assay (see
Materials and methods). Cell–cell fusion was determined
by the formation of multinucleated cells (syncytia) in co-
cultures and co-localization of calcein/CMTMR in fused
cells. Incubation of GM95 cells transiently expressing CD4
and CXCR4 with HIV-1IIIB Env-expressing HeLa cells for
2–16 h at 37jC did not result in the formation of multinu-
cleated cells (Fig. 1A, panel a, phase). The inability of
GM95 to promote HIV-1 Env-mediated fusion was further
confirmed by lack of co-localization of calcein and
CMTMR between fusing partners (not shown). To rule out
the possibility of defective processing and expression of
CD4 or CXCR4 in GSL-deficient mutant GM95 cells, we
incubated GM95 targets with cells expressing HIV-2SBL/ISY
Env, which utilizes CD4 and CXCR4 for fusion but does not
require presence of GSL in the target membrane (Hug et al.,
2000). The presence of multinucleated cells (Fig. 1A,
panel c, phase) as well as distribution of calcein in the
multinucleated cells (Fig. 1A, panel d, calcein) demonstrates
that massive fusion occurred with human immunodeficiency
virus type 2 (HIV-2) Env-expressing cells.
To confirm that HIV-2 Env-mediated fusion of GM95
cells occurred subsequent to the HIV-2 Env, CD4, and
CXCR4 interactions, we tested fusion activity of GM95
cells expressing either CD4 (infected with vCB3) or
CXCR4 (infected with vacc-CXCR4). We did not observe
any fusion when GM95 cells expressing either CD4 or
CXCR4 alone were incubated with HIV-2 Env-expressing
cells (data not shown). Therefore, the CD4 and CXCR4
expressed in GM95 cells were sufficient for HIV-2 Env but
not HIV-1 Env-mediated fusion.
Previous studies show that HIV-1 entry is critically
dependent on the surface density of the chemokine receptors
(Platt et al., 1998; Reeves et al., 2002). Analysis of surface
expressed CD4 and CXCR4 in GM95 cells (Fig. 1B) showed
that the receptor levels were significantly lower when
compared with the NIH3T3 cell lines (see Figs. 2C, D).
Fig. 1B shows cell surface expression of CD4 (left panel)
and CXCR4 (right panel) levels in GM95 cells following
infection with the vaccinia recombinants vCB3 and vacc-
CXCR4, respectively.
To determine whether the lack of HIV-1 fusion observed
in GM95 cells (Fig. 1A) was due to low CD4 and CXCR4
levels, we generated stable transfectants of GM95 cells
expressing CD4 and major coreceptors CXCR4 or CCR5
using the retroviral transduction strategy. Using this ap-
proach, GM95 cells expressed high levels of CXCR4,
CCR5, and CD4 (Figs. 2C, D). Since GM95 cells are
derived from GSL+ MEB4 cells (Hidari et al., 1996), we
attempted to engineer CD4 and chemokine receptors into
MEB4 cells in our initial studies. However, extremely poor
expression and concurrent rapid loss of cell-surface-
Fig. 1. HIV-1 Env-mediated fusion of GM95 cells transiently expressing CD4 and CXCR4. GM95 cells were simultaneously infected with the vaccinia
recombinants, vCB3 (encoding human CD4) and vacc-CXCR4 (encoding wild-type human CXCR4) at 10 m.o.i. for 10–16 h at 37jC. To express viral
envelope glycoproteins, sub-confluent monolayers of HeLa cells were infected with the vaccinia recombinants vSC50 (encoding the gene for HIV-2SBL/ISY
envelope) or vPE16 (encoding the gene for HIV-1Lai, BH8 envelope) at the 10 m.o.i. for 10–16 h at 37jC. For fusion assay, we labeled CD4, CXCR4-
expressing GM95 cells (targets, plated over night on 12-well clusters) with Calcein-AM, and HIV Env-expressing cells with CMTMR, following
manufacturer’s directions. Target and effector cells (105 cells of each type) were cultured together in 12 well plates for 2–16 h at 37jC. Images were collected
using a 20 objective. Phase and calcein fluorescence images are shown in (A). Cell surface expression of CD4 and CXCR4 following infection with vCB3
and vacc-CXCR4 was confirmed by immunostaining using PE-conjugated anti-CD4 and anti-CXCR4 (12G5) Mabs by FACS (B).
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study. As an alternative, we compared HIV-1 Env-mediated
fusion of GM95 cells with another mouse fibroblast cell
line, NIH3T3, which has been previously engineered to
express HIV-1 receptors (Deng et al., 1997).
We next assayed the fusion activity of GM95 cell lines
expressing high levels of HIV-1 receptors by using
fluorescence microscopy. When fluorescently labeledGM95CD4X4 and HIV-1 EnvIIIB-expressing HeLa cells
were incubated for 2–4 h at 37jC, significant fusion
occurred (Fig. 2A, panels a–c). Similar results were
obtained when fluorescently labeled GM95CD4R5/HIV-
1BaL Env-expressing cell pairs were incubated under the
identical conditions (Fig. 2B, panels a–c). GSL+ NIH3T3
targets also fused with high efficiency with matching HIV-1
Env-expressing cells as expected (Figs. 2A, B, panels d–f).
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calcein/CMTMR within the boundaries of multinucleated
cells (Figs. 2A, B). These findings show that higher expres-
sion of CD4 and chemokine receptors in GM95 cells renders
them susceptible to HIV-1 Env-mediated fusion. On the other
hand, GM95 cells expressing low receptor levels (Fig. 1B)
did not fuse with HIV-1 Env-expressing cells (see Fig. 1A).
Therefore, target membrane GSLs play a role in HIV-1 fusion
at low receptor(s) density. The results presented here were
reproducible from at least three independent experiments. We
did not observe any fusion when GM95CD4X4 cells were
incubated with HIV-1BaL Env-expressing HeLa cells or whenFig. 2. (A and B) HIV-1 Env-mediated fusion of GM95 cells constitutively expres
well tissue culture plates at 105 cells per well and were labeled with the cytoplasm
with the vaccinia recombinant vPE16 (HIV-1Lai, BH8 envelope) or vCB43 (HIV-1
with calcein AM. Effector cells (1–2  105) were added to the wells containing C
incubations, images were collected using a 20 objective and fusion was assess
GM95CD4X4 targets; (d– f) 3T3CD4X4 targets. (B, a–c) GM95CD4R5 targets; (d
the figure. (C and D) Surface expression of CD4, CXCR4, and CCR5. GM95 ce
were generated as described in Materials and methods. The cells harvested with
incubated with 20-Al PE-conjugated mouse IgG (anti-CXCR4 (12G5), anti-CCR5
determined by FACS as described in Materials and methods. Mouse IgG1n-PE-con
used as isotype controls for CD4 and chemokine receptors, respectively. (C
NIH3T3CD4X4 cells (as indicated). (D) Surface expression of CD4 and CCR5 iGM95CD4R5 cells were incubated with HIV-1IIIB Env-
expressing cells (data not shown).
Temperature dependence of fusion of GM95 targets
Previous studies show that HIV-1 Env-mediated fusion
occurs only at or above 28jC with an optimum at 37jC, and
no fusion is observed at 25jC (Frey et al., 1995; Jernigan et
al., 2000). Cellular CD4 associates with GSL-enriched
microdomains (Manes et al., 2000). CXCR4 is known to
interact with GM3 in the presence of purified HIV-1 gp120
(Sorice et al., 2001). Therefore, GSLs may influence recep-sing CD4 and CXCR4 or CCR5. Target cells were plated overnight on 12-
ic dye CMTMR. To express HIV-1 Env, HeLa effector cells were infected
BaL envelope). The next day, HIV-1 Env-expressing HeLa cells were labeled
MTMR-labeled target cells and incubated for 3–6 h at 37jC. At the end of
ed by overlap of red/green fluorescence as described in the text. (A, a–c)
– f) 3T3CD4R5 targets. Phase, calcein, and CMTMR panels are indicated in
ll lines constitutively expressing huCD4, wt-hu-CXCR4, and wt-hu-CCR5
cell dissociation buffer were respuspended in 100-Al PBS (106 cells) and
(2D7), or RPA-T4 (BD-Pharmingen). Surface expression of receptors was
jugated Mab and mouse IgG2an-PE-conjugated Mab (BD-Pharmingen) were
) Surface expression of CD4 and CXCR4 cells in GM95CD4X4 and
n GM95CD4R5 and NIH3T3CD4R5 cells as indicated.
Fig. 2 (continued).
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absence of GSL in the target membrane modulates lateral
mobility of HIV-1 receptors, we monitored fusion activity of
GM95CD4X4 cells at various temperatures using the dye-
transfer assay (see Materials and methods). To decrease the
effect of nonspecific dye transfer by vaccinia infection
during longer incubation periods, we utilized TF228 cells,
which constitutively express HIV-1 EnvIIIB envelope, to
monitor fusion at low temperatures. Remarkably,
GM95CD4X4 cells fused at 25jC when incubated with
TF228 cells for 3–6 h (Fig. 3A, open bars, NIH3T3CD4X4;
black bars, GM95CD4X4). On the other hand, we did not
observe any fusion of NIH3T3CD4X4 cells at 25jC under
identical conditions, consistent with the previous reports
(Jernigan et al., 2000; Frey et al., 1995). The data presentedin Figs. 3A, B show fusion extents at 6-h incubations at the
indicated temperatures and are expressed as mean values (F
standard deviation) of five to seven samples within a single
experiment. The results were reproducible from at least
three independent experiments. Prolonged incubations of
NIH3T3CD4X4/TF228 cell pairs (up to 12 h) at 25jC did
not show an increase in fusion above background of the
assay (not shown) confirming that NIH3T3 targets did not
support fusion at 25jC. Interestingly, fusion activity of
GM95 cells at 31jC was still higher when compared with
NIH3T3CD4X4 cells (Fig. 3A), whereas we did not see any
difference in extents of fusion at 37jC (Fig. 3A), consistent
with our kinetics data (not shown). GM95 fusion at 25jC
was inhibited in the presence of the peptide C34 known to
block six helix bundle formations (Chan et al., 1998)
Fig. 3. Temperature dependence of HIV-1 Env-mediated fusion with
GM95CD4X4 Cells. Targets cells were plated on 12-well plates and labeled
with CMTMR as mentioned in Fig. 2. TF228 cells were labeled with
CMFDA following the manufacturer’s directions. Dye-labeled TF228 cells
(106 per well) were added to the CMTMR-labeled target cells and samples
were incubated at 25, 31, or 37jC in an incubator pre-equilibrated at
desired temperature and 5% CO2 for 3–6 h (A). At the end of incubations,
images were collected using a 20 objective and fusion was calculated as
described in the Materials and methods. In some wells, C34 (2 AM final
concentration) was added during co-culture (B). C34 is a peptide inhibitor
derived from HIV gp41. The results are representative from at least three
independent experiments.
Fig. 4. Effect of cholesterol depletion on HIV-1 Env-mediated fusion of
GM95 cells. Target cells on 12-well plates were labeled with CMTMR and
then treated with 5 or 10 mM MehCD for 30 min at 37jC, essentially as
described earlier (Viard et al., 2002). CMFDA-labeled HIV-1 Env-
expressing cells were added to the matching targets and the samples were
incubated at 37jC for 2–4 h. Percent fusion was determined as described in
Materials and methods (A, target cells bearing CD4 and CXCR4, co-
cultured with HIV-1IIIB Env-expressing HeLa cells; B, target cells bearing
CD4 and CCR5, co-cultured with HIV-1BaL Env-expressing HeLa cells). To
assess recovery of fusion of GM95 cells, cholesterol-depleted targets were
incubated with MehCD–cholesterol mixture for 60 min at 37jC (Viard et
al., 2002), and fusion with HIV-1 Env-expressing HeLa cells was monitored
for 2–4 h at 37jC (C). To observe the effect of PPMP on fusion, CD4,
CXCR4-bearing targets cells were cultured in the presence of 5–10 AM
PPMP for 48–72 h. Fusion with HIV-1IIIB Env-expressing cells was
followed as described earlier (Hug et al., 2000).
S.S. Rawat et al. / Virology 318 (2004) 55–6560confirming that the dye transfer observed at low temperature
reflected HIV-1 Env-mediated membrane fusion (Fig. 3B).
HIV-1 Env-mediated fusion with GM95 and NIH3T3 targets
at 37jC was also inhibited in the presence of C34 as
expected (Fig. 3B; Gallo et al., 2001). The results were
reproducible for at least three independent experiments.
Cholesterol depletion from GM95 targets blocks fusion
We have previously shown that depletion of cholesterol
from CD4+ targets expressing low coreceptors blocks fu-
sion, whereas cells expressing high coreceptors remain
insensitive to cholesterol removal (Viard et al., 2002). We
reasoned that at a high density of receptors, clustering is not
the rate-limiting step. In contrast, GSL depletion from cell
lines expressing high levels of receptors (such as HOS and
NIH3T3) reduced fusion by c50% (Hug et al., 2000),
suggesting that GSL may promote fusion by stabilizing thereceptor-envelope complexes via specific interactions (Fan-
tini et al., 2000). Therefore, we tested the effect of choles-
terol depletion from the GM95 cells on subsequent fusion
with HIV-1 Env-expressing cells. Fusion activity of choles-
terol-depleted GM95 cells before and after pretreatment
with methyl-h-cyclodextrin (MehCD) is shown in Figs.
4A, B. The values are expressed as fusion relative to that
of untreated cells (normalized to 100%) as an average (F
S.D.) of five to seven samples from a single experiment.
When cells were pretreated with 5 or 10 mM MehCD, we
observed a 50–75% decrease in fusion of GM95CD4X4
(Fig. 4A) and GM95CD4R5 cells (Fig. 4B). However,
fusion activity of NIH3T3 targets was only slightly reduced
(c10%) even after treatment with higher MehCD concen-
tration (10 mM) consistent with previously reported findings
(Viard et al., 2002). Addition of cholesterol from a mixture
of MehCD/cholesterol to GM95 targets pretreated with 10
mM MehCD) rescued HIV-1 Env-mediated fusion to orig-
inal levels (Fig. 4C, open bars, GM95CD4R5; black bars,
GM95CD4X4).
Fig. 4 (continued ).
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cells with the GSL-biosynthesis inhibitor 1-phenyl-2-hexa-
decanoylamino-3-morpholino-1-propanol (PPMP) decreases
subsequent HIV-1 fusion (Hug et al., 2000). However, it is
likely that PPMP treatment could also modulate otherFig. 5. Effect of cytochalasin B on HIV-1 Env-mediated fusion of GM95CD4X4 an
the absence or presence of 10 AM cytochalasin B, and fusion was scored as desccellular lipids and generate lipid-metabolites in the target
cells. To further evaluate the specific effects of PPMP to
reduce GSLs, we pretreated targets with the PPMP for 48–
72 h at 37jC (see Materials and methods). When target cells
were pretreated with PPMP, we observed a 50–70% reduc-
tion in fusion of NIH3T3CD4X4 cells, but fusion of
GM95CD4X4 cells remained unaffected (Fig. 4D, as indi-
cated). These results demonstrate that block in HIV-1 fusion
and entry in PPMP-treated GSL+ cells are primarily due to
the depletion of GSLs and not a consequence of nonspecific
adverse effects on target cells (Hug et al., 2000).
Cytoskeletal network disruption blocks fusion of GM95
targets
Cytoskeletal elements are known to play a role in HIV-
1 entry and fusion (Frey et al., 1995; Jernigan et al., 2000).
An active cytoskeleton provides receptor/coreceptor clus-
tering especially at low receptors availability (Singer et al.,
2001; Valensin et al., 2002). Therefore, we examined the
fusion of GM95 cells in the presence of cytochalasin B, an
agent that interferes with a variety of cellular movements
such as actin polymerization and cytokinesis (Forscher and
Smith, 1988).
When GM95 targets expressing cognate receptors were
cultured with HIV-1 Env-expressing cells at 37jC for 2–4
h in the presence of 10 Ag/ml of cytochalasin B, we
observed significant decrease (z 80%) in fusion (Fig. 5,
as indicated). The fusion activity of GM95 and NIH3T3
targets in the absence or presence of cytochalasin B is
shown in Fig. 5. The values are expressed as an average (F
S.D.) from five to seven samples within a single experiment
and normalized to fusion in the absence of cytochalasin B
as 100% with the corresponding cell pairs. The decrease ind GM95CD4R5 cells. Cell–cell fusion was monitored for 2–4 h at 37jC in
ribed in Fig. 2.
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GM95CD4X4 as well as GM95CD4R5 cells. In contrast,
fusion activity of NIH3T3 targets remained unaffected in
the presence of cytochalasin B (Fig. 5, as indicated)
consistent with previous observations (Viard et al., 2002).Discussion
Previously, we have used PPMP, one of the specific
inhibitors of GlcCer synthase (Abe et al., 1992). We showed
that inhibition of GSL biosynthesis in various cell lines by
treatment with PPMP reduced their susceptibility to CD4 and
coreceptor-dependent HIV-1 fusion (Hug et al., 2000; Puri et
al., 1998). The synthesis of most GSLs begins with glucosy-
lation of ceramide to form glucosylceramide (GlcCer), the
precursor for complex glycosphingolipids (Ichikawa and
Hirabayashi, 1998; Kolter et al., 2002). This cerebroside is
synthesized from uridine diphosphate glucose and ceramide
by glucosyl transferase, GlcCer synthase. One way to better
understand the functions of GSLs is to selectively inhibit
cellular glucosylceramide formation by using specific inhib-
itors of GlcCer synthase or to knock out the gene encoding
this enzyme. In this paper, we used a GlcCer synthase
‘‘knock-out’’ cell line (Ichikawa et al., 1994) to examine
the role of GSL in HIV-1 Env-mediated fusion. We show that
these cells are perfectly capable of supporting HIV-1 Env-
mediated fusion when they were engineered to express
relatively high levels of CD4, CXCR4, or CCR5.
How can our observation that GSL-deficient cells fuse be
reconciled with our previous studies using PPMP to inhibit
GSL biosynthesis? It could be argued that treatment of cells
by PPMP generates other metabolites in the GSL biosyn-
thesis pathway that may cause reduction of HIV-1 Env-
mediated fusion. Indeed, it has been shown that treatment of
cells with PPMP and its analogues enhance ceramide levels
in these cells (Abe et al., 1995; Maurer et al., 2000; Shay-
man et al., 1991) by blocking GlcCer synthase as well as 1-
O-acylceramide synthase (Lee et al., 1999). We had argued
against such possible side effects because the susceptibility
of PPMP-treated GSL+ cells to HIV-1 Env-mediated fusion
can be completely recovered following reconstitution with
purified GSLs (Hug et al., 2000). Moreover, treatment of
GM95 cells bearing CD4 and coreceptors with PPMP did
not affect their susceptibility to HIV-1 Env-mediated fusion.
However, these arguments need to be reassessed in the light
of current data.
If our original hypothesis is correct, that GSL bolsters
HIV-1 Env-mediated fusion, the extent of fusion of GM95
cells bearing CD4 and coreceptor should be enhanced by
introduction of GSLs into the membranes of these cells. The
experiment shown in Fig. 1 was carried out with GM95
expressing low levels of CD4 and CXCR4 following
transient expression of their genes. The stable cells lines
expressed relatively high levels of HIV-1 receptors, and
fusion appeared to be optimal (Fig. 2) so little enhancementwould be expected by introducing GSLs into their mem-
branes. Our attempts to select a population of GM95 cells
with low levels of CD4 and coreceptor were unsuccessful.
Therefore, it was not possible to design an experiment that
would allow the observation of a possible enhancement of
the extent of HIV-1 Env-mediated fusion following addition
of GSL to these cells.
When we compared rates of HIV-1 Env-mediated fusion,
we find that the HIV-1 receptor-bearing GSL GM95 cells
fuse more efficiently as compared with GSL+ NIH3T3 cells
bearing similar levels of CD4 and coreceptors (data not
shown). The differences in fusion phenotype became appar-
ent at the lower temperatures below 37jC. At 25jC, the
difference became even more pronounced because the
fusion with NIH3T3CD4X4 was not observable, whereas
considerable fusion with GM95CD4X4 was seen (Fig. 3).
We speculate that the target membrane GSLs interact with
the receptors and HIV-1 envelope and thus modulate sub-
sequent fusion events.
The GM95 cells bearing CD4 and coreceptor exhibited
additional differences in fusion phenotype in that their
susceptibility was dependent on normal levels of cholesterol
and intact cytoskeletal architecture (Figs. 4 and 5). Previous-
ly, we had shown that the effects of cholesterol removal on
HIV-1 Env-mediated fusion are dependent on HIV-1 receptor
levels (Viard et al., 2002). Similarly, it seems that GSLs affect
HIV-1 Env-mediated fusion in different ways depending on
levels of coreceptor expression. At low levels of coreceptor
expression, GSLs appear to be required for fusion (Fig. 1),
whereas at high coreceptor levels, they decrease the fusion
efficiency at the lower temperatures (Fig. 3). The probability
of coreceptor engagement is enhanced by localization of CD4
clusters at a reasonable distance from coreceptor clusters
(Singer et al., 2001; Viard et al., 2002). At high coreceptor
surface densities, GSLs are not required because activated
Envs will readily find coreceptors in their vicinity. However,
at low surface density of coreceptor, GSLs may be required to
hold activated Env for a sufficient amount of time to scan the
surface and find coreceptors that need to be engaged. Studies
on binding of gp120 to GSL are consistent with this notion
(Fantini et al., 2000).Materials and methods
Materials
Fluorescent probes were obtained from Molecular Probes
(Eugene, OR), and tissue culture media were obtained from
Gibco/BRL (Gaithersburg, MD). Other reagents were from
Sigma (St Louis, MO). PE-conjugated anti-CD4, CXCR4,
or CCR5 monoclonal antibodies were from BD-Pharmingen
(San Jose, CA). Source, preparation, and amplification of
various plasmids used to generate stable CD4/CXCR4/
CCR5 transfectants are described elsewhere (Garber et al.,
1998).
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and vacc-CXCR4 (Chabot et al., 2000), were a gift from
Chris Broder (USUHS, Bethesda, MD). vSC50 (Chakrabarti
et al., 1990) was obtained through the AIDS reagent and
Reference Program (NIAID, NIH). vPE16 (Earl et al., 1991)
and vCB43 (Broder and Berger, 1995) were gifts from Dr. P.
Earl, C.C. Broder, and B. Moss. The inhibitor C34 was
synthesized by Macromolecular Resources (Fort Collins,
CO). The sequence of this peptide is WMEWDREINNYT-
SLIHSLIEESQNQQEKNEQELL.
Cells
GM95 cells (Ichikawa et al., 1994) were obtained from
Riken Cell bank (Tsukuba Science City, Japan) and main-
tained in culture in DMEM with 10% heat-inactivated
serum with antibiotics (D10). Absence of GSLs in GM95
cells was reconfirmed by routine lipid analysis (Ablan et al.,
2001). NIH3T3CD4CXCR4 (termed here as 3T3CD4X4)
and NIH3T3CD4CCR5 cells (termed here as 3T3CD4R5) (a
gift from Dan Littman) (Garber et al., 1998) were grown in
D10+ 3 Ag/ml puromycin. HeLa and 293T cell lines were
maintained in D10. TF228.1.16 cells (a kind gift from
Zdenka L. Jonak, SmithKline Beecham Pharmaceuticals,
Pennsylvania; Jonak et al., 1993) were maintained as
suspension culture using RPMI-1640 supplemented with
10% heat-inactivated serum and antibiotics.
HIV-1 envelope expression
HIV envelope proteins were transiently expressed on
the surface of HeLa cells using the recombinant vac-
cinia constructs vPE16 (HIV-1IIIB, X4-utilizing), vSC50
(HIV-2SBL/ISY, X4-utilizing), and vCB43 (HIV-1BaL, R5-
utilizing) as described previously (Gallo et al., 2001). To
study temperature dependence of GM95 fusion, we used
TF228 cells, a B lymphocyte cell line that is constitutively
expressing HIV-1IIIB envelope.
CD4, CXCR4, and CCR5 expression in GM95 cells
For transient receptor expression, we used the vaccinia
recombinants vCB3 (encoding the full-length gene of
human CD4 molecule) and vacc-CXCR4 (expressing
wild-type human CXCR4) for CD4 and CXCR4 expres-
sions, respectively. Cells were infected with the cor-
responding vaccinia virus at 10 m.o.i. for 16–20 h at
37jC (Jernigan et al., 2000). Surface expression of CD4
was confirmed by Western blot analysis using T4-4
antibody and by FACS analysis using PE-conjugated
anti-CD4 Mab (RPA-T4). CXCR4 expression was
assessed by staining with the PE-conjugated anti-CXCR4
Mab (12G5). We used mouse IgG1n-PE-conjugated Mab
and mouse IgG2an-PE-conjugated Mab (BD-Pharmingen
as isotype controls for CD4 and chemokine receptors
immunostaining.Alternatively, huCD4, wt-hu-CXCR4, and wt-hu-CCR5
were stably inserted into GM95 cells by using the replica-
tion competent VSV-pseudoytped MLV-based viruses bear-
ing CXCR4 or CD4. A DNA mixture containing 2-Ag pJK3
(expressing MLV gag and pol genes), 1-Ag pL-VSV-G, 0.5-
Ag pCMV-Tat, and 3-Ag pMX-CXCR4 or pMX-CCR5 was
transfected into 293T cells on six well plates containing 2-
ml D10 per well using calcium phosphate transfection
protocol (Stratagene #200385) according to manufacturer’s
directions. The virus supernatants were collected at 48 h and
clarified by centrifugation for 5 min at 2000 rpm followed
by filtration through 0.45-Am filters. Supernatants were used
immediately for infecting the target cells.
GM95 cells on six well plates (50000 per well) were
infected with CXCR4 or CCR5 bearing virus particles (2
ml/well) in the presence of 10-Ag/ml polybrene (Sigma) for
2–4 h at 37jC. Cells were washed in fresh culture media
and transferred into T25-culture flasks until confluent. Cells
were stained with PE-conjugated 12G5 or 2D7 Mab and
sorted for 100% expression. Cells stably expressing core-
ceptors were subsequently infected with CD4 virus-contain-
ing supernatant and sorted for positive expression of CD4 as
above. The cells expressing CD4 and CXCR4 were desig-
nated as GM95CD4X4 and the cells expressing CD4 and
CCR5 were named as GM95CD4R5.
Analysis of surface expressed CD4, CXCR4, and CCR5 on
GM95 cells by FACS
The cells were harvested with a cell dissociation buffer
from Gibco/BRL, centrifuged at 450  g, and resuspended
at 106 cells/ml in PBS with 5% FBS and 5% normal mouse
serum (NMS). After incubating for 15 min at 4jC, cells
were washed twice in PBS with 0.1% BSA and resuspended
at 107 cells/ml (in 100 Al) in PBS with 5% FBS and 5%
NMS. PE-conjugated mouse IgG anti-CD4 (RPA-T4), PE-
conjugated mouse IgG anti-CXCR4 (12G5), or PE-conju-
gated mouse IgG anti-CCR5 (2D7) from Pharmingen (San
Diego, CA) was then added to each sample at a 1:5 dilution.
Cells were incubated at 4jC for 1 h and washed twice in
PBS with 0.1% BSA. Samples were resuspended in 1 ml of
PBS to be read by a FACScalibur (Becton Dickinson, San
Jose, CA) at 10000 events/sample with respect to unlabeled
cells.
Fusion assay
Cell–cell fusion between CD4+ targets and HIV-1 Env-
expressing effector cells was assayed using the fluorescent
dye-transfer method (Puri et al., 2002). We used the fluo-
rescent dyes CMTMR (green emission, ex/em 540/566 nm),
CMFDA (blue emission, ex/em 492/516 nm), or Calcein
(blue emission, ex/em 496/517 nm) to label the cells for
fusion assay.
Typically, target cells were plated on 12-well clusters at a
density of 50000 cells/well 1 day before fusion experiments
S.S. Rawat et al. / Virology 318 (2004) 55–6564and were labeled with the cytoplasmic dye CMTMR at a
concentration of 10 AM for 1 h at 37jC. Envelope-express-
ing cells were labeled with CMFDA (10 AM) or Calcein-
AM (0.5–1 AM) for 1–2 h at 37jC according to manufac-
turer’s instructions. Fluorescently labeled effector and target
cells were co-cultured under various experimental condi-
tions. Details of specific culture conditions of the specified
experiments are described in the figure legends. Dye redis-
tribution was monitored microscopically as described pre-
viously (Puri et al., 1998). The extent of fusion was
calculated as percent fusion = 100  number of bound
cells positive for both dyes/number of bound cells positive
for CMTMR labeled target cells.
GSL depletion by treatment with PPMP
Target cells were incubated with the GSL biosynthesis
inhibitor, 1-phenyl-2-hexadecanoylamino-3-morpholino-1-
propanol (PPMP), before fusion assay essentially as de-
scribed (Hug et al., 2000). Fusion was monitored in the
presence of inhibitor-containing culture medium.
Cholesterol depletion from target cells
Cholesterol depletion and subsequent addition to the
target cells were done using methyl-h-cyclodextrin as de-
scribed (Viard et al., 2002). Cholesterol levels in the cells
were assayed using the cholesterol assay kit (Molecular
Probes).
Cytochalasin treatment
Fluorescently labeled target and effector cells were co-
cultured for 2–4 h at 37jC on 12-well plates (as described
above) in the absence or presence with 10 AM cytochalasin
B (Sigma). Cell–cell fusion was assayed by co-localization
of red/green dyes as described above.Acknowledgments
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